DDInter998 DDInter1094
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ivermectin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Ivermectin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is downregulated by {v} (Compound) Danazol
Danazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) ERBB3
ERBB3 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ivermectin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Lorlatinib
Ivermectin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Ivermectin (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ivermectin (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Lorlatinib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Ivermectin (Compound) upregulates ERBB3 (Gene) and ERBB3 (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ivermectin (Compound) upregulates ERBB3 (Gene) and ERBB3 (Gene) is bound by Dasatinib (Compound) and ERBB3 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ivermectin (Compound) upregulates ERBB3 (Gene) and ERBB3 (Gene) is bound by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Lorlatinib